|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
HU215180B
(hu)
|
1992-01-23 |
1998-10-28 |
Merck Patent Gmbh. |
Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
GB9720054D0
(en)
|
1997-09-19 |
1997-11-19 |
Celltech Therapeutics Ltd |
Biological products
|
|
GB9824437D0
(en)
|
1998-11-06 |
1999-01-06 |
Ylo Herttuala Seppo |
Gene therapy
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
ES2655912T3
(es)
|
2002-11-08 |
2018-02-22 |
Ablynx N.V. |
Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
|
|
ES2551439T5
(es)
|
2003-07-01 |
2018-11-08 |
Ucb Biopharma Sprl |
Fragmentos Fab de anticuerpos modificados
|
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
GB0315457D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
WO2005049094A1
(en)
|
2003-11-13 |
2005-06-02 |
Advantagene, Inc. |
A mixed complementary viral vector for gene therapy
|
|
EP1789446A2
(en)
|
2004-09-02 |
2007-05-30 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
SG158150A1
(en)
|
2004-12-21 |
2010-01-29 |
Centocor Inc |
Anti-il-12 antibodies, epitopes, compositions, methods and uses
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
EP2220120A2
(en)
|
2007-11-27 |
2010-08-25 |
Ablynx N.V. |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
JP5816170B2
(ja)
|
2009-06-26 |
2015-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
WO2012094623A2
(en)
|
2011-01-07 |
2012-07-12 |
Abbott Laboratories |
Anti-il-12/il-23 antibodies and uses thereof
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2925785A4
(en)
|
2012-11-28 |
2016-11-16 |
Zymeworks Inc |
MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF
|
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
US10047167B2
(en)
|
2013-03-15 |
2018-08-14 |
Eli Lilly And Company |
Methods for producing fabs and bi-specific antibodies
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
US20170216387A1
(en)
|
2014-08-01 |
2017-08-03 |
Illycaffe' S.P.A. |
Roasted laurina coffee, method for its preparation, and use for preventing metabolic syndrome
|
|
CA2981312C
(en)
|
2015-03-30 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
PL3368572T3
(pl)
|
2015-10-02 |
2022-09-12 |
Symphogen A/S |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
SG11201802912PA
(en)
*
|
2015-10-10 |
2018-05-30 |
Intrexon Corp |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
|
WO2017125815A2
(en)
|
2016-01-22 |
2017-07-27 |
MabQuest SA |
Immunological reagents
|
|
AU2017241776B2
(en)
|
2016-03-29 |
2024-06-20 |
Janssen Biotech, Inc. |
Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
|
|
MA45779A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Polypeptides immunomdulateurs et compositions et procédés associés
|
|
MX386014B
(es)
|
2016-08-10 |
2025-03-18 |
Univ Ajou Ind Academic Coop Found |
Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
|
|
MY203971A
(en)
|
2016-10-13 |
2024-07-26 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Anti-lag-3 antibodies and compositions
|
|
US20190367611A1
(en)
|
2017-02-01 |
2019-12-05 |
CentryMed Pharmaceutical Inc. |
Monomeric human igg1 fc and bispecific antibodies
|
|
SG11201912240QA
(en)
|
2017-06-28 |
2020-01-30 |
Regeneron Pharma |
Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
|
|
CN110396133B
(zh)
|
2018-04-25 |
2021-07-23 |
免疫靶向有限公司 |
一种以白介素12为活性成分的融合蛋白型药物前体
|
|
CA3100005A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
AU2019333047A1
(en)
|
2018-08-30 |
2020-12-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
EP3766512A1
(en)
|
2019-07-16 |
2021-01-20 |
Universität Zürich |
Fc-modified il-12 for local cns delivery
|
|
MX2022000991A
(es)
|
2019-07-25 |
2022-05-24 |
Univ Chicago |
Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
|
|
US20220356221A1
(en)
|
2019-09-28 |
2022-11-10 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
CN115916233A
(zh)
|
2019-10-03 |
2023-04-04 |
Xencor股份有限公司 |
靶向IL-12异源二聚体Fc融合蛋白
|
|
BR112022012112A2
(pt)
|
2019-12-20 |
2022-09-06 |
Regeneron Pharma |
Agonistas de il2 e métodos de uso dos mesmos
|
|
JP7773991B2
(ja)
|
2020-03-23 |
2025-11-20 |
ザイムワークス ビーシー インコーポレイテッド |
マスクされたｉｌ１２融合タンパク質及びその使用方法
|
|
AU2021248919A1
(en)
|
2020-04-01 |
2022-10-13 |
Xilio Development, Inc. |
Masked IL-12 cytokines and their cleavage products
|
|
IL297186A
(en)
*
|
2020-04-17 |
2022-12-01 |
Univ Leland Stanford Junior |
Transgenic il-12 and il-23 polypeptides and their uses
|
|
WO2022155263A2
(en)
|
2021-01-12 |
2022-07-21 |
Askgene Pharma Inc. |
Chimeric molecules comprising il-12 agonist polypeptide
|
|
US20240228586A1
(en)
|
2021-05-07 |
2024-07-11 |
The University Of Chicago |
Compositions and methods comprising protease-activated therapeutic agents
|